Showing 1 - 12 results of 12 for search 'David K Simon', query time: 0.06s Refine Results
  1. 1
    VPS35 and the mitochondria: Connecting the dots in Parkinson's disease pathophysiology

    VPS35 and the mitochondria: Connecting the dots in Parkinson's disease pathophysiology by Gianni Cutillo, David K. Simon, Simona Eleuteri

    Published 2020-11-01
    Get full text
    Article
  2. 2
    Do Somatic Mitochondrial DNA Mutations Contribute to Parkinson's Disease?

    Do Somatic Mitochondrial DNA Mutations Contribute to Parkinson's Disease? by Joanne Clark, Ying Dai, David K. Simon

    Published 2011-01-01
    Get full text
    Article
  3. 3
    Mitochondria and Parkinson's Disease

    Mitochondria and Parkinson's Disease by David K. Simon, Charleen T. Chu, Russell H. Swerdlow

    Published 2011-01-01
    Get full text
    Article
  4. 4
    Mitochondrial DNA mutations in Parkinson's disease brain

    Mitochondrial DNA mutations in Parkinson's disease brain by David K. Simon, Joanne Clark Matott, Janaina Espinosa, Neeta A. Abraham

    Published 2017-04-01
    Get full text
    Article
  5. 5
    Efficacy of Deep Brain Stimulation in a Patient with Genetically Confirmed Chorea-Acanthocytosis

    Efficacy of Deep Brain Stimulation in a Patient with Genetically Confirmed Chorea-Acanthocytosis by Alby Richard, Joey Hsu, Patricia Baum, Ron Alterman, David K. Simon

    Published 2019-06-01
    Get full text
    Article
  6. 6
    Associations between exercise classes and self-reported exercise by people with Parkinson’s disease at Parkinson’s foundation centers of excellence

    Associations between exercise classes and self-reported exercise by people with Parkinson’s disease at Parkinson’s foundation centers of excellence by Ella Nettnin, Stephanie Burrows, Guanhong Miao, Samuel S. Wu, David K. Simon, Miriam R. Rafferty

    Published 2022-01-01
    Get full text
    Article
  7. 7
    Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice.

    Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. by Joanne Clark, Elizabeth L Clore, Kangni Zheng, Anthony Adame, Eliezer Masliah, David K Simon

    Published 2010-01-01
    Get full text
    Article
  8. 8
    Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration

    Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration by Emmanuel Quansah, Wouter Peelaerts, J. William Langston, David K. Simon, Jerry Colca, Patrik Brundin

    Published 2018-05-01
    Get full text
    Article
  9. 9
    Targeting the PARylation-Dependent Ubiquitination Signaling Pathway for Cancer Therapies

    Targeting the PARylation-Dependent Ubiquitination Signaling Pathway for Cancer Therapies by Daoyuan Huang, Jingchao Wang, Li Chen, Weiwei Jiang, Hiroyuki Inuzuka, David K. Simon, Wenyi Wei

    Published 2025-02-01
    Get full text
    Article
  10. 10
    Pgc-1α overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf.

    Pgc-1α overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf. by Joanne Clark, Jessica M Silvaggi, Tomas Kiselak, Kangni Zheng, Elizabeth L Clore, Ying Dai, Caroline E Bass, David K Simon

    Published 2012-01-01
    Get full text
    Article
  11. 11
    No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.

    No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial. by Chizoba C Umeh, Adriana Pérez, Erika F Augustine, Rohit Dhall, Richard B Dewey, Zoltan Mari, David K Simon, Anne-Marie A Wills, Chadwick W Christine, Jay S Schneider, Oksana Suchowersky

    Published 2014-01-01
    Get full text
    Article
  12. 12
    Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease mouse model

    Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease mouse model by Tracy-Shi Zhang Fang, Yu Sun, Andrew C. Pearce, Simona Eleuteri, Mark Kemp, Christopher A. Luckhurst, Rachel Williams, Ross Mills, Sarah Almond, Laura Burzynski, Nóra M. Márkus, Christopher J. Lelliott, Natasha A. Karp, David J. Adams, Stephen P. Jackson, Jin-Feng Zhao, Ian G. Ganley, Paul W. Thompson, Gabriel Balmus, David K. Simon

    Published 2023-11-01
    Get full text
    Article

Search Tools: